Hatteras Venture Partners

Hatteras Venture Partners is a venture capital and private equity firm specializing in buyouts, pre-seed, seed/startup, early stage, emerging growth, growth capital, and mid venture stages. The firm is an SBIC. It typically invests in life sciences and healthcare companies with a focus on biopharmaceuticals, medical devices, medical device research and development, diagnostics, healthcare IT and health related technologies, and services opportunities in human medicine and health. The firm primarily invests in companies located in the research-driven and capitally-underserved regions of Mid Atlantic such as North Carolina and the Southeastern United States. It seeks to invest between $0.5 million and $4 million initially; and between $5 million and $20 million in total.

TypeInvestor
HQDurham, NC, US
Founded2000
Size (employees)23 (est)
Websitehatterasvp.com
Cybersecurity ratingBMore
Hatteras Venture Partners was founded in 2000 and is headquartered in Durham, NC, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Hatteras Venture Partners

Myla Lai-Goldman

Myla Lai-Goldman

Venture Partner
Jeff Terrell

Jeff Terrell

Associate
Christy Shaffer

Christy Shaffer

General Partner
Ben Scruggs

Ben Scruggs

Associate
Show more

Hatteras Venture Partners Office Locations

Hatteras Venture Partners has an office in Durham
Durham, NC, US (HQ)
280 S Mangum St #350
Show all (1)

Hatteras Venture Partners Online and Social Media Presence

Embed Graph

Hatteras Venture Partners Blogs

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other research programs in Parkinson’s diseaseacquired from Lysosomal Therapeutics, Inc• R&D team led by Peter Lansbu…

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast G…

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C., July 29, 2020 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy compa…

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development to participate equally in US cost and profit sharing – CAMBRIDGE, Mass. (July 9, 2020) – Kymera Therapeutics Inc. today announced t…

Shattuck Labs Announces Closing of $118 Million Series B Financing

Financing will advance two ARC™ clinical programs and expand pipeline development —   DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class …

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome B…
Show more

Hatteras Venture Partners Frequently Asked Questions

  • When was Hatteras Venture Partners founded?

    Hatteras Venture Partners was founded in 2000.

  • Who are Hatteras Venture Partners key executives?

    Hatteras Venture Partners's key executives are Myla Lai-Goldman, Jeff Terrell and Christy Shaffer.

  • How many employees does Hatteras Venture Partners have?

    Hatteras Venture Partners has 23 employees.

  • Where is Hatteras Venture Partners headquarters?

    Hatteras Venture Partners headquarters is located at 280 S Mangum St #350, Durham.

  • Where are Hatteras Venture Partners offices?

    Hatteras Venture Partners has an office in Durham.

  • How many offices does Hatteras Venture Partners have?

    Hatteras Venture Partners has 1 office.